Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E et al (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407–2418
2. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G et al (2017) Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 377(20):1930–1942
3. Yamamura Y, Nakamura S, Itoh S et al (1998) OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287:860–867
4. Boertien WE, Meijer E, Li J, Bost JE, Struck J, Flessner MF, Gansevoort RT, Torres VE (2013) Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis 61(3):420–429
5. Torres VE, Harris PC (2014) Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol 25(1):18–32
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献